{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:33:07Z","timestamp":1789032787260,"version":"build-2803163510"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ejpb.2019.07.013","type":"journal-article","created":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T02:06:15Z","timestamp":1562897175000},"page":"411-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Intestinal absorption-modifying excipients: A current update on preclinical in vivo evaluations"],"prefix":"10.1016","volume":"142","author":[{"given":"D.","family":"Dahlgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sj\u00f6blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lennern\u00e4s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2019.07.013_b0005","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1021\/acs.molpharmaceut.7b00353","article-title":"Preclinical effect of absorption modifying excipients on rat intestinal transport of five model compounds and the intestinal barrier marker 51Cr-EDTA","volume":"14","author":"Dahlgren","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.07.013_b0010","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.xphs.2016.02.028","article-title":"Effect of common excipients on the oral drug absorption of biopharmaceutics classification system class 3 drugs cimetidine and acyclovir","volume":"105","author":"Vaithianathan","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.013_b0015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2125.1995.tb04466.x","article-title":"The effects of pharmaceutical excipients on small intestinal transit","volume":"39","author":"Adkin","year":"1995","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.ejpb.2019.07.013_b0020","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1208\/s12248-016-9928-8","article-title":"The effects of pharmaceutical excipients on gastrointestinal tract metabolic enzymes and transporters\u2014an update","volume":"18","author":"Zhang","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2019.07.013_b0025","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1208\/s12248-013-9509-z","article-title":"Impact of osmotically active excipients on bioavailability and bioequivalence of BCS class III drugs","volume":"15","author":"Chen","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2019.07.013_b0030","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/jps.2600841205","article-title":"The effect of mannitol on the oral bioavailability of cimetidine","volume":"84","author":"Adkin","year":"1995","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.013_b0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11095-006-9120-4","article-title":"A modern view of excipient effects on bioequivalence: case study of sorbitol","volume":"24","author":"Chen","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.07.013_b0040","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1023\/A:1016488623022","article-title":"Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo","volume":"13","author":"Lue\u00dfen","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.07.013_b0045","first-page":"345","article-title":"Floating drug delivery systems to increase gastric retention of drugs: a review","volume":"1","author":"Mayavanshi","year":"2008","journal-title":"Res. J. Pharm. Technol."},{"key":"10.1016\/j.ejpb.2019.07.013_b0050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ejps.2008.11.002","article-title":"Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo","volume":"36","author":"Ren","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.013_b0055","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.addr.2007.08.017","article-title":"The effects of pharmaceutical excipients on drug disposition","volume":"59","author":"Buggins","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2019.07.013_b0060","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.07.013_b0065","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1023\/A:1015892621261","article-title":"Predicting fraction dose absorbed in humans using a macroscopic mass balance approach","volume":"8","author":"Sinko","year":"1991","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.07.013_b0070","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1023\/A:1015888813741","article-title":"Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man","volume":"9","author":"Lennern\u00e4s","year":"1992","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.07.013_b0075","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1021\/acs.molpharmaceut.6b00514","article-title":"Regional intestinal permeability of three model drugs in human","volume":"13","author":"Dahlgren","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.07.013_b0080","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1021\/acs.molpharmaceut.6b00515","article-title":"Regional intestinal permeability in dogs: biopharmaceutical aspects for development of oral modified-release dosage forms","volume":"13","author":"Dahlgren","year":"2016","journal-title":"Mol Pharm."},{"key":"10.1016\/j.ejpb.2019.07.013_b0085","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrd3187","article-title":"Coexistence of passive and carrier-mediated processes in drug transport","volume":"9","author":"Sugano","year":"2010","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.ejpb.2019.07.013_b0090","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/jps.24258","article-title":"Direct in vivo human intestinal permeability (Peff) determined with different clinical perfusion and intubation methods","volume":"104","author":"Dahlgren","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.013_b0095","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1021\/js970218s","article-title":"Membrane transport of drugs in different regions of the intestinal tract of the rat","volume":"87","author":"Ungell","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.013_b0100","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/00498250701704819","article-title":"Intestinal permeability and its relevance for absorption and elimination","volume":"37","author":"Lennernas","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejpb.2019.07.013_b0105","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1021\/jm9810102","article-title":"Lennern\u00e4s H, Karl\u00e9n A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. a multivariate data analysis approach","volume":"41","author":"Winiwarter","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2019.07.013_b0110","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1021\/mp1001119","article-title":"Aqueous boundary layers related to oral absorption of a drug: from dissolution of a drug to carrier mediated transport and intestinal wall metabolism","volume":"7","author":"Sugano","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.07.013_b0115","doi-asserted-by":"crossref","first-page":"G922","DOI":"10.1152\/ajpgi.2001.280.5.G922","article-title":"The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo","volume":"280","author":"Atuma","year":"2001","journal-title":"American J. Physiol. Gastrointestinal Liver Physiol."},{"key":"10.1016\/j.ejpb.2019.07.013_b0120","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.addr.2016.07.007","article-title":"Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues","volume":"106","author":"Lundquist","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2019.07.013_b0125","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1021\/acs.molpharmaceut.7b00279","article-title":"Regional intestinal permeability in rats: a comparison of methods","volume":"14","author":"Roos","year":"2017","journal-title":"Mol Pharm."},{"key":"10.1016\/j.ejpb.2019.07.013_b0130","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1021\/js960503w","article-title":"Diffusion of drugs in native and purified gastrointestinal mucus","volume":"86","author":"Larhed","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.013_b0135","first-page":"361","article-title":"Investigations into the diffusion behaviour of polypeptides in native intestinal mucus with regard to their peroral administration","volume":"2","author":"Bernkop-Schn\u00fcrch","year":"1996","journal-title":"Pharm. Pharmacol. Commun."},{"key":"10.1016\/j.ejpb.2019.07.013_b0140","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejpb.2018.09.022","article-title":"Jejunal absorption of aprepitant from nanosuspensions: Role of particle size, prandial state and mucus layer","volume":"132","author":"Roos","year":"2018","journal-title":"Eur J Pharm Biopharm."},{"key":"10.1016\/j.ejpb.2019.07.013_b0145","doi-asserted-by":"crossref","first-page":"e1361900","DOI":"10.1080\/21688370.2017.1361900","article-title":"Intestinal surfactant permeation enhancers and their interaction with enterocyte cell membranes in a mucosal explant system","volume":"5","author":"Danielsen","year":"2017","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.ejpb.2019.07.013_b0150","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0304-4157(83)90004-7","article-title":"Solubilization of phospholipids by detergents structural and kinetic aspects","volume":"737","author":"Lichtenberg","year":"1983","journal-title":"Biochimica et Biophysica Acta (BBA)-Rev. Biomembr."},{"key":"10.1016\/j.ejpb.2019.07.013_b0155","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.addr.2016.06.005","article-title":"Intestinal permeation enhancers for oral peptide delivery","volume":"106","author":"Maher","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2019.07.013_b0160","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1023\/A:1018965328626","article-title":"Evidence for an interaction between the \u03b2-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration\u2013time profile","volume":"10","author":"Lennern\u00e4s","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.07.013_b0165","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijpharm.2018.04.006","article-title":"Polysorbate 20 alters the oral bioavailability of etoposide in wild type and mdr1a deficient Sprague-Dawley rats","volume":"543","author":"Al-Ali","year":"2018","journal-title":"Int J Pharm."},{"key":"10.1016\/j.ejpb.2019.07.013_b0170","series-title":"Physiology of the Gastrointestinal Tract","first-page":"587","article-title":"Tight junctions and the intestinal barrier","author":"Ma","year":"2018"},{"key":"10.1016\/j.ejpb.2019.07.013_b0175","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.biomaterials.2012.09.051","article-title":"Sodium caprate as an enhancer of macromolecule permeation across tricellular tight junctions of intestinal cells","volume":"34","author":"Krug","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2019.07.013_b0180","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.addr.2009.09.006","article-title":"Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic","volume":"61","author":"Maher","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2019.07.013_b0185","doi-asserted-by":"crossref","first-page":"G360","DOI":"10.1152\/ajpgi.00428.2002","article-title":"Hypotonicity-induced increases in duodenal mucosal permeability facilitates adjustment of luminal osmolality","volume":"285","author":"Nylander","year":"2003","journal-title":"American J. Physiol. Gastrointest Liver Physiol."},{"key":"10.1016\/j.ejpb.2019.07.013_b0190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0169-409X(00)00046-6","article-title":"Show me the pathway!: Regulation of paracellular permeability by Na+-glucose cotransport","volume":"41","author":"Turner","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2019.07.013_b0195","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1023\/A:1016220428705","article-title":"Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation?","volume":"12","author":"Lennern\u00e4s","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.07.013_b0200","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijpharm.2018.07.057","article-title":"Effect of absorption-modifying excipients, hypotonicity, and enteric neural activity in an in vivo model for small intestinal transport","volume":"549","author":"Dahlgren","year":"2018","journal-title":"Int J Pharm."},{"key":"10.1016\/j.ejpb.2019.07.013_b0205","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1124\/mol.64.6.1530","article-title":"A new principle for tight junction modulation based on occludin peptides","volume":"64","author":"Tavelin","year":"2003","journal-title":"Mol Pharmacol."},{"key":"10.1016\/j.ejpb.2019.07.013_b0210","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1124\/mol.104.008375","article-title":"A novel strategy for the enhancement of drug absorption using a claudin modulator","volume":"67","author":"Kondoh","year":"2005","journal-title":"Mol Pharmacol."},{"key":"10.1016\/j.ejpb.2019.07.013_b0215","unstructured":"FDA, Bioeqvivalence and Bioavailability Guideline. <https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm389370.pdf>."},{"key":"10.1016\/j.ejpb.2019.07.013_b0220","unstructured":"EMA, Bioeqvivalence and Bioavailability Guideline. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003519.pdf>."},{"key":"10.1016\/j.ejpb.2019.07.013_b0225","unstructured":"FDA, BCS Guidance for Industry, 12 August 2014. <www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070246.pdf>."},{"key":"10.1016\/j.ejpb.2019.07.013_b0230","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejps.2014.09.004","article-title":"Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: impact on bioequivalence","volume":"65","author":"Garc\u00eda-Arieta","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.013_b0235","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.xphs.2016.01.005","article-title":"On the Effect of Common Excipients on the Oral Absorption of Class 3 Drugs","volume":"105","author":"Garc\u00eda-Arieta","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.013_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2018.08.032","article-title":"Oral peptide delivery: Translational challenges due to physiological effects","author":"Tyagi","year":"2018","journal-title":"J Control Release."},{"key":"10.1016\/j.ejpb.2019.07.013_b0245","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1007\/s11095-007-9488-9","article-title":"Safe and effective permeation enhancers for oral drug delivery","volume":"25","author":"Whitehead","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.07.013_b0250","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jsps.2014.06.004","article-title":"A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives","volume":"24","author":"Muheem","year":"2016","journal-title":"Saudi Pharmaceut. J."},{"key":"10.1016\/j.ejpb.2019.07.013_b0255","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.peptides.2017.12.014","article-title":"Oral delivery of anti-diabetes therapeutics using cell penetrating and transcytosing peptide strategies","volume":"100","author":"Rehmani","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.ejpb.2019.07.013_b0260","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1023\/A:1016289200422","article-title":"The effect of absorption enhancers on the oral absorption of the GP IIB\/IIIA receptor antagonist, DMP 728, in rats and dogs","volume":"12","author":"Burcham","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.07.013_b0265","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.2042-7158.1981.tb13796.x","article-title":"Enhanced rectal absorption of insulin and heparin in rats in the presence of non-surfactant adjuvants","volume":"33","author":"Nishihata","year":"1981","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2019.07.013_b0270","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.addr.2016.02.004","article-title":"Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials","volume":"106","author":"Aguirre","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2019.07.013_b0275","doi-asserted-by":"crossref","first-page":"e1176822","DOI":"10.1080\/21688370.2016.1176822","article-title":"Safety concerns over the use of intestinal permeation enhancers: a mini-review","volume":"4","author":"McCartney","year":"2016","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.ejpb.2019.07.013_b0280","article-title":"< i> In vitro<\/i> models for the prediction of< i> in vivo<\/i> performance of oral dosage forms","author":"Kostewicz","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.013_b0285","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejps.2014.02.010","article-title":"In vivo methods for drug absorption\u2013comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation\/API\/excipient characterization including food effects","volume":"57","author":"Sj\u00f6gren","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.013_b0290","article-title":"Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique","author":"Sj\u00f6berg","year":"2012","journal-title":"Eur. J. Pharm. Sci"},{"key":"10.1016\/j.ejpb.2019.07.013_b0295","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jps.2600790604","article-title":"Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorbtive (Caco-2) cells","volume":"79","author":"Artursson","year":"1990","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.013_b0300","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1124\/dmd.109.029363","article-title":"Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil","volume":"37","author":"Bergman","year":"2009","journal-title":"Drug Metabolism Disposit."},{"key":"10.1016\/j.ejpb.2019.07.013_b0305","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0928-0987(97)00070-5","article-title":"In vivo non-linear intestinal permeability of celiprolol and propranolol in conscious dogs: evidence for intestinal secretion","volume":"6","author":"Lipka","year":"1998","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.013_b0310","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijpharm.2018.05.029","article-title":"The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs","volume":"547","author":"Dahlgren","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.07.013_b0315","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijpharm.2018.01.008","article-title":"Effects of surfactant-based permeation enhancers on mannitol permeability, histology, and electrogenic ion transport responses in excised rat colonic mucosae","volume":"539","author":"Maher","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.07.013_b0320","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1023\/A:1018909210879","article-title":"Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route","volume":"10","author":"Anderberg","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.07.013_b0325","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1023\/A:1012160102740","article-title":"Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement","volume":"14","author":"Schipper","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.07.013_b0330","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1023\/A:1018984731584","article-title":"Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility","volume":"11","author":"Swenson","year":"1994","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.07.013_b0335","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0928-0987(99)00032-9","article-title":"Chitosans as absorption enhancers of poorly absorbable drugs: 3: Influence of mucus on absorption enhancement","volume":"8","author":"Schipper","year":"1999","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.013_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2018.09.001","article-title":"Time-dependent effects on small intestinal transport by absorption-modifying excipients","author":"Dahlgren","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ejpb.2019.07.013_b0345","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1021\/mp500210c","article-title":"Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state","volume":"11","author":"Mudie","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.07.013_b0350","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2036.2005.02683.x","article-title":"Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging","volume":"22","author":"Schiller","year":"2005","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.ejpb.2019.07.013_b0355","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ejps.2012.08.010","article-title":"Evaluation of alkylmaltosides as intestinal permeation enhancers: comparison between rat intestinal mucosal sheets and Caco-2 monolayers","volume":"47","author":"Petersen","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.013_b0360","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nri2653","article-title":"Intestinal mucosal barrier function in health and disease","volume":"9","author":"Turner","year":"2009","journal-title":"Nature Rev. Immunol."},{"key":"10.1016\/j.ejpb.2019.07.013_b0365","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0378-5173(98)00288-9","article-title":"The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations","volume":"176","author":"Baluom","year":"1998","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.07.013_b0370","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/pharmaceutics11010041","article-title":"Application of permeation enhancers in oral delivery of macromolecules: an update","volume":"11","author":"Maher","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2019.07.013_b0375","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1021\/la048711o","article-title":"Influence of pH, ionic strength, and temperature on self-association and interactions of sodium dodecyl sulfate in the absence and presence of chitosan","volume":"21","author":"Thongngam","year":"2005","journal-title":"Langmuir"},{"key":"10.1016\/j.ejpb.2019.07.013_b0380","first-page":"3","article-title":"Determination of critical micelar concentration of anionic surfactants using surfactants-sensible electrodes","volume":"1","author":"Mihali","year":"2008","journal-title":"Measurement."},{"key":"10.1016\/j.ejpb.2019.07.013_b0385","first-page":"68","article-title":"Acid-base equilibria and related properites of chitosan","volume":"4","author":"Kwang-hee","year":"1983","journal-title":"Bulletin Korean Chem. Soc."},{"key":"10.1016\/j.ejpb.2019.07.013_b0390","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1021\/mp500776a","article-title":"Interaction with mixed micelles in the intestine attenuates the permeation enhancing potential of alkyl-maltosides","volume":"12","author":"Gradauer","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.07.013_b0395","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1053\/j.gastro.2016.07.008","article-title":"Inflammation and the intestinal barrier: Leukocyte\u2013epithelial cell interactions, cell junction remodeling, and mucosal repair","volume":"151","author":"Luissint","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejpb.2019.07.013_b0400","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrgastro.2012.32","article-title":"The enteric nervous system and neurogastroenterology","volume":"9","author":"Furness","year":"2012","journal-title":"Nature Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejpb.2019.07.013_b0405","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.pathol.4.110807.092135","article-title":"Epithelial barriers in homeostasis and disease","volume":"5","author":"Marchiando","year":"2010","journal-title":"Annual Rev. Patholog. Mech. Dis."},{"key":"10.1016\/j.ejpb.2019.07.013_b0410","doi-asserted-by":"crossref","first-page":"G274","DOI":"10.1152\/ajpgi.1989.257.2.G274","article-title":"Villus contraction aids repair of intestinal epithelium after injury.","volume":"257","author":"Moore","year":"1989","journal-title":"American J. Physiol. Gastrointest Liver Physiol."},{"key":"10.1016\/j.ejpb.2019.07.013_b0415","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1152\/physrev.00012.2006","article-title":"Restoration of barrier function in injured intestinal mucosa","volume":"87","author":"Blikslager","year":"2007","journal-title":"Physiol Rev."},{"key":"10.1016\/j.ejpb.2019.07.013_b0420","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrm3721","article-title":"Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration","volume":"15","author":"Barker","year":"2014","journal-title":"Nature Rev. Mol. Cell Biol."},{"issue":"1208\u20131218","key":"10.1016\/j.ejpb.2019.07.013_b0425","first-page":"e1202","article-title":"The epithelial barrier is maintained by in vivo tight junction expansion during pathologic intestinal epithelial shedding","volume":"140","author":"Marchiando","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejpb.2019.07.013_b0430","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/jps.21084","article-title":"Oral delivery of antisense oligonucleotides in man","volume":"97","author":"Tillman","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.013_b0435","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12020-011-9492-z","article-title":"Desmopressin duration of antidiuretic action in patients with central diabetes insipidus","volume":"40","author":"Juul","year":"2011","journal-title":"Endocrine"},{"key":"10.1016\/j.ejpb.2019.07.013_b0440","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s40262-017-0528-2","article-title":"Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment","volume":"56","author":"Marbury","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2019.07.013_b0445","doi-asserted-by":"crossref","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.ejpb.2019.07.013_b0450","series-title":"Handbook of pharmaceutical excipients","author":"Rowe","year":"2006"},{"key":"10.1016\/j.ejpb.2019.07.013_b0455","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijpharm.2005.10.036","article-title":"The evaluation of some pharmaceutically acceptable excipients as permeation enhancers for amoxicillin","volume":"308","author":"Legen","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.07.013_b0460","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/jps.2600820412","article-title":"Epithelial transport of drugs in cell culture. VIII: effects of sodium dodecyl sulfate on cell membrane and tight junction permeability in human intestinal epithelial (Caco-2) cells","volume":"82","author":"Anderberg","year":"1993","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.013_b0465","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11095-007-9509-8","article-title":"Evaluation of mucosal damage and recovery in the gastrointestinal tract of rats by a penetration enhancer","volume":"25","author":"Narkar","year":"2008","journal-title":"Pharm. Res."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641119302516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641119302516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:39:09Z","timestamp":1760546349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641119302516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":93,"alternative-id":["S0939641119302516"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.07.013","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intestinal absorption-modifying excipients: A current update on preclinical in vivo evaluations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}